172@29@17@248!~!172@29@0@53!~!|news|business|earnings|aurobindo-pharma-q4-pat-seen-up-17-8-yoy-to-rs-641-6-cr-kotak-3844161.html!~!news|moneycontrol|com!~!|controller|infinite_scroll_article.php!~!is_mobile=false
Moneycontrol
FREE virtual training session on Passive Income Secrets: October 24 and 25, 2020, 10am to 1pm. Register Now!
Last Updated : Apr 17, 2019 03:10 PM IST | Source: Moneycontrol.com

Aurobindo Pharma Q4 PAT seen up 17.8% YoY to Rs. 641.6 cr: Kotak

Net Sales are expected to increase by 26.5 percent Y-o-Y (down 2.8 percent Q-o-Q) to Rs. 5,121.6 crore, according to Kotak.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Kotak has come out with its fourth quarter (January-March’ 19) earnings estimates for the Pharmaceuticals sector. The brokerage house expects Aurobindo Pharma to report net profit at Rs. 641.6 crore up 17.8% year-on-year (down 9.9% quarter-on-quarter).


Net Sales are expected to increase by 26.5 percent Y-o-Y (down 2.8 percent Q-o-Q) to Rs. 5,121.6 crore, according to Kotak.


Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to rise by 27 percent Y-o-Y (down 6 percent Q-o-Q) to Rs. 1,021.4 crore.


Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

First Published on Apr 17, 2019 03:10 pm
Sections